Loading stock data…
$28.54-0.45 (-1.55%)
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Rapport Therapeutics, Inc. in the Healthcare sector is trading at $28.54 with a market capitalization of $2.1B. Wall Street consensus targets $63.04 (13 analysts), implying a +120.9% move over the next 12 months. The stock is currently near its 52-week low of $23.75, remaining 20.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $20.00M | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$60.81M↓ | -$24.21M↑ | -$38.51M↓ | -$29.99M↓ | -$29.50M |
| Net Income | -$56.62M↓ | -$19.86M↑ | -$33.76M↓ | -$26.93M↓ | -$26.73M |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The comp...